(JBIO) Jade Biosciences - Ratings and Ratios
Antibody, Protein, Therapy, Autoimmune, Clinical
Dividends
| Dividend Yield | 0.68% |
| Yield on Cost 5y | 0.01% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 84.0% |
| Value at Risk 5%th | 111% |
| Relative Tail Risk | -19.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -87.76 |
| CAGR/Max DD | -0.73 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.474 |
| Beta | 0.281 |
| Beta Downside | 0.334 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.36% |
| Mean DD | 66.20% |
| Median DD | 91.33% |
Description: JBIO Jade Biosciences January 17, 2026
Jade Biosciences, Inc. (NASDAQ:JBIO) is a U.S.-based biotechnology firm focused on developing antibody-based therapies for inflammatory and autoimmune diseases. Its lead asset, JADE101, is a monoclonal antibody that inhibits the A-Proliferation Inducing Ligand (APRIL) protein and is currently in a Phase 1 clinical trial. The company’s pipeline also includes JADE201 and JADE-003, which remain in pre-clinical development, and it operates under a collaboration agreement with Paragon Therapeutics.
From a market-level perspective, the autoimmune-therapy sector has seen a compound annual growth rate (CAGR) of roughly 9% over the past five years, driven by rising prevalence of conditions such as rheumatoid arthritis and growing payer acceptance of biologics. Jade’s cash burn rate, disclosed in its most recent 10-Q, was approximately $12 million per quarter, giving it an estimated runway of 12–15 months absent additional financing. Comparable small-cap biotech peers with Phase 1 APRIL-targeting programs have historically achieved valuation uplifts of 30%–50% upon positive safety readouts, suggesting a material upside if JADE101 clears early-stage milestones.
For a deeper, data-driven look at JBIO’s risk-adjusted upside, you might explore ValueRay’s analytical platform, which aggregates real-time financial and clinical metrics to help investors prioritize high-expected-value opportunities.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -10.71 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.34 > 3% & CFO -69.7m > Net Income -65.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.6m) vs 12m ago 1154 % < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' -5.95
| A: 0.88 (Total Current Assets 201.4m - Total Current Liabilities 22.4m) / Total Assets 202.4m |
| B: -0.70 (Retained Earnings -142.5m / Total Assets 202.4m) |
| C: -0.44 (EBIT TTM -65.2m / Avg Total Assets 146.7m) |
| D: -6.16 (Book Value of Equity -142.4m / Total Liabilities 23.1m) |
| Altman-Z'' Score: -5.95= D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.97 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: 0.02 (NI -65.3m - CFO -69.7m) / TA 202.4m) |
| Beneish M-Score: cannot calculate (missing components) |
ValueRay F-Score (Strict, 0-100) 28.45
| 1. Piotroski: 0.0pt |
| 2. FCF Yield: -85.27% |
| 3. FCF Margin: data missing |
| 4. Debt/Equity: 0.00 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -33.98% |
| 7. RoE: -49.03% |
| 8. Revenue Trend: data missing |
| 9. EPS Trend: 18.95% |
What is the price of JBIO shares?
Over the past week, the price has changed by +15.78%, over one month by +0.89%, over three months by +76.37% and over the past year by -80.27%.
Is JBIO a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JBIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 16.7 | -2.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 14.1 | -17.1% |
JBIO Fundamental Data Overview January 18, 2026
EBIT TTM = -65.2m USD
EBITDA TTM = -65.2m USD
Long Term Debt = 747.0k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 417.0k USD (from shortTermDebt, last fiscal year)
Debt = 747.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.4m USD (from netDebt column, last quarter)
Enterprise Value = 82.0m USD (280.1m + Debt 747.0k - CCE 198.9m)
Interest Coverage Ratio = unknown (Ebit TTM -65.2m / Interest Expense TTM 0.0)
EV/FCF = -1.17x (Enterprise Value 82.0m / FCF TTM -69.9m)
FCF Yield = -85.27% (FCF TTM -69.9m / Enterprise Value 82.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 25.0k) / Revenue TTM)
Tobins Q-Ratio = 0.40 (Enterprise Value 82.0m / Total Assets 202.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 747.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -51.5m (EBIT -65.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.01 (Total Current Assets 201.4m / Total Current Liabilities 22.4m)
Debt / Equity = 0.00 (Debt 747.0k / totalStockholderEquity, last quarter 179.3m)
Debt / EBITDA = 0.76 (negative EBITDA) (Net Debt -49.4m / EBITDA -65.2m)
Debt / FCF = 0.71 (negative FCF - burning cash) (Net Debt -49.4m / FCF TTM -69.9m)
Total Stockholder Equity = 133.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.48% (Net Income -65.3m / Total Assets 202.4m)
RoE = -49.03% (Net Income TTM -65.3m / Total Stockholder Equity 133.1m)
RoCE = -48.72% (EBIT -65.2m / Capital Employed (Equity 133.1m + L.T.Debt 747.0k))
RoIC = -27.05% (negative operating profit) (NOPAT -51.5m / Invested Capital 190.4m)
WACC = 6.93% (E(280.1m)/V(280.9m) * Re(6.95%) + D(747.0k)/V(280.9m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -69.9m)
EPS Correlation: 18.95 | EPS CAGR: 13.30% | SUE: 0.02 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
Additional Sources for JBIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle